PRODUCT1 | Indication | Pre-clinical | Phase 1/2 | Phase 3 | Commercial | |
---|---|---|---|---|---|---|
Talicia® | H. pylori infection2 | APPROVED BY U.S. FDA NOVEMBER 2019 |
||||
MOVANTIK® | Opioid induced constipation3 | GLOBAL RIGHTS EXCLUDING EUROPE, CANADA, ISRAEL |
||||
Aemcolo® | Travelers' Diarrhea4 | U.S. EXCLUSIVE LICENSE |
||||
RHB-204 | NTM infections | |||||
RHB-104 | Crohn's disease | |||||
RHB-102 (Bekinda®) |
Gastroenteritis & gastritis | |||||
IBS-D | ||||||
RHB-106 | Bowel cleanser | |||||
Opaganib (Yeliva®) |
Oncology indications and COVID-19 | |||||
RHB-107 upamostat |
Oncology/GI and COVID-19 |
It is with great sadness that we announce the passing of our beloved friend and colleague, Patrick McLean, who passed away on Feb. 8, 2021
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases.